Heart Failure
American College of Cardiology, American Heart Association, Heart Failure Society of AmericaPublished: April 1, 2022
- Overview
- Top 10 Take-Home Messages
- Assessment
- Treatment
- Tables
- Stages of HF
- Classification of HF by LVEF
- Other Potential Nonischemic Causes of HF
- Selected Potential Causes of Elevated Natriuretic Peptide Levels
- Examples of Factors Implicating Possible Genetic Cardiomyopathy
- Potential Barriers to Effective HF Self-Care and Example Interventions
- Commonly Used Oral Diuretics in Treatment of Congestion for Chronic HF
- Selected Prescription Medications That May Cause or Exacerbate HF
- Drugs Commonly Used for HFrEF (Stage C HF)
- Benefits of Evidence-Based Therapies for Patients With HFrEF
- ESC Definition of Advanced HF
- INTERMACS Profiles
- Clinical Indicators of Advanced HF
- Indications and Contraindications to Durable Mechanical Support
- Intravenous Inotropic Agents Used in the Management of HF
- Common Factors Precipitating HF Hospitalization With Acute Decompensated HF
- Suggested Shock Clinical Criteria
- Suggested Shock Hemodynamic Criteria
- Society for Cardiovascular Angiography and Interventions (SCAI) Cardiogenic Shock Criteria
- Important Components of a Transitional Care Plan
- Most Common Co-Occurring Chronic Conditions Among Medicare Beneficiaries With HF (N=4,947,918), 2011
- Risk of HF and Outcomes in Special Populations
- Cancer Therapies Known to Be Associated With Cardiomyopathy
- Risk Factors for Cancer Therapy–Related Cardiomyopathy
- HF Management Strategies Across the Pregnancy Continuum
- Palliative and Supportive Care Domains to Improve Processes of Care and Patient Outcomes
- Figures and Algorithms
- ACC/AHA Stages of HF
- Trajectory of Class C HF
- Classification and Trajectories of HF Based on LVEF
- Diagnostic Algorithm for HF and EF-Based Classification
- Recommendations (Class 1 and 2a) for Patients at Risk of HF (Stage A) and Those With Pre-HF (Stage B)
- Treatment of HFrEF Stages C and D
- Additional Medical Therapies for Patients With HFrEF
- Algorithm for CRT Indications in Patients With Cardiomyopathy or HFrEF
- Additional Device Therapies
- Treatment Approach in Secondary Mitral Regurgitation
- Recommendations for Patients With Mildly Reduced LVEF (41%– 49%)
- Recommendations for Patients With Preserved LVEF (≥50%)
- Diagnostic and Treatment of Transthyretin Cardiac Amyloidosis Algorithm
- Recommendations for Treatment of Patients With HF and Selected Comorbidities
- A Depiction of the Clinical Course of HF With Associated Types and Intensities of Available Therapies Over Time
Also Found In
You rely on Guideline Central for transparency
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.